B
BioInvent International AB
STO:BINV
BioInvent International AB
STO:BINV
Price:
23
SEK
-2.34%
Market Cap:
kr1.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
B
|
BioInvent International AB
STO:BINV
|
SE |
|
A
|
Autogrill SpA
MIL:AGL
|
IT |
|
O
|
Openbase Inc
KOSDAQ:049480
|
KR |
|
Airtificial Intelligence Structures SA
F:IRG
|
ES |
|
O
|
Oscar Mitra Sukses Sejahtera Tbk PT
IDX:OLIV
|
ID |
|
C
|
Castelbajac Co Ltd
KOSDAQ:308100
|
KR |
|
G
|
Great Southern Copper PLC
LSE:GSCU
|
UK |
|
M
|
MoneyHero Ltd
NASDAQ:MNY
|
SG |
|
National Grid PLC
NYSE:NGG
|
UK |
|
G
|
Global Consumer PCL
SET:GLOCON
|
TH |
|
Community Bank System Inc
NYSE:CBU
|
US |
|
Ureru Net Advertising Group Co Ltd
TSE:9235
|
JP |
|
Cahya Mata Sarawak Bhd
OTC:CHYMF
|
MY |
|
Condor Gold PLC
LSE:CNR
|
UK |
Multiples-Based Value
The Multiples-Based Value of one BINV stock under the Base Case scenario is hidden SEK. Compared to the current market price of 23 SEK, BioInvent International AB is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BINV Multiples-Based Value
LOCKED
Multiples Across Competitors
BINV Competitors Multiples
BioInvent International AB Competitors
BioInvent International AB Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
B
|
BioInvent International AB
STO:BINV
|
1.5B SEK | 6.7 | -4.5 | -2.8 | -2.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.4B USD | 5.8 | 85.4 | 14.2 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.6B USD | 5 | 23.6 | 13.8 | 13.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.9B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.3B USD | 9 | 27.4 | 20.5 | 21.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.7B USD | 5.5 | 17.6 | 13.1 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3 | 33.2 | 11.2 | 14 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.4 | 39.6 | 40.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
